Jillian Thomsen is recorded as Chief Accounting Officer at Nektar Therapeutics (NKTR). The newest filing on record that lists Jillian Thomsen as Chief Accounting Officer at Nektar Therapeutics (NKTR) is dated April 29, 2020. Nektar Therapeutics reported in an 8-K filed June 23, 2023 that Jillian Thomsen was terminated as Chief Financial Officer, effective June 16, 2023. Nektar Therapeutics reported in an 8-K filed April 17, 2023 that Jillian Thomsen resigned as Chief Financial Officer, effective April 17, 2023. The proxy statement of Nektar Therapeutics reports total compensation of $1,239,759 for Jillian Thomsen in fiscal 2023, including a base salary of $355,760. Disclosed compensation is on record for 2 fiscal years. Jillian Thomsen has spoken on 2 earnings calls across 1 company, most recently for Nektar Therapeutics on November 3, 2022. Nektar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nektar Therapeutics includes Howard Robin (CEO), Linda Rubinstein (CFO), Sandra Gardiner (CFO) and 1 other.
“On April 17, 2023, Nektar Therapeutics (the "Company") announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023 (the "Notice Date"). On June 19, 2023, the Company and Ms. Thomsen entered into an Employment Separation and Release Agreement (the "Agreement") in connection with the termination of Ms. Thomsen's employment with the Company as of June 16, 2023 (the "Separation Date").”
Nektar Therapeutics Form 8-K, filed June 23, 2023
· Read the filing
“On April 17, 2023, Jillian Thomsen stepped down as the Chief Financial Officer of the Company and will depart the Company in June 2023 following a transition period.”
Nektar Therapeutics Form 8-K, filed April 17, 2023
· Read the filing
Jillian Thomsen on recent calls
“We ended the third quarter with $546 million in cash and investments and no debt. Our 2022 financial guidance remains unchanged, and we expect to end the year with approximately $450 million in cash and investments.”
“As Howard noted earlier, we have made significant progress in executing our restructuring plan and implementing our revised strategic plan. Our 2022 financial guidance, which we provided during our April call, remains unchanged.”
